

Non-alcoholic Steatohepatitis Treatment Market 2026

<https://marketpublishers.com/r/N21D5997818CEN.html>

Date: November 2025

Pages: 210

Price: US\$ 2,999.00 (Single User License)

ID: N21D5997818CEN

Abstracts

The Non-alcoholic Steatohepatitis Treatment Market was valued at in and is anticipated to reach by , at a CAGR of 0.54 from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Non-alcoholic Steatohepatitis Treatment Market.

This report delivers a comprehensive overview of the Non-alcoholic Steatohepatitis Treatment Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Non-alcoholic Steatohepatitis Treatment Market. The Non-alcoholic Steatohepatitis Treatment Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for —.

Non-alcoholic Steatohepatitis Treatment Market Scope:

By DRUG

Vitamin E

Pioglitazone

Ocaliva

Elafibranor

Selonsertib & Cenicriviroc

Others

By DISTRIBUTION CHANNELS

Hospital pharmacy

Retail pharmacy

Online providers

Key Players

Allergan plc.

Pfizer Inc

Gilead Sciences, Inc.

Genfit SA

Novartis AG

Intercepts Pharmaceuticals

Cadila Healthcare Ltd

Novo Nordisk

Raptor Pharmaceutical Corp.

Galmed Pharmaceuticals Ltd.

Major Highlights

This report delivers a comprehensive overview of the Non-alcoholic Steatohepatitis Treatment Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Non-alcoholic Steatohepatitis Treatment Market. The Non-alcoholic Steatohepatitis Treatment Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for —.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

South America (Colombia, Brazil, Argentina, Rest of South America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification

Increase Your Customer Base by 3X using our Partner Identification tool

Uncover strategic collaboration opportunities with DataM vetted partners aligned

to your ecosystem.

Identify high potential M&A targets based on synergies, market positioning and growth trajectory.

Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?

Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.

Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.

White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.

Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.

Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.

Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

Contents

1. SCOPE AND METHODOLOGY

- 1.1. Research Methodology
- 1.2. Scope of the market

2. KEY TRENDS AND DEVELOPMENTS

- 2.1. Key Trends and Developments

3. EXECUTIVE SUMMARY

- 3.1. Market Snippet By Distribution Channels
- 3.2. Market Snippet By Drug
- 3.3. Market Snippet By Region
- 3.4. DataM CLO Scenario

4. GLOBAL NASH (NON-ALCOHOLIC STEATOHEPATITIS) TREATMENT MARKET DYNAMICS

- 4.1. Market impacting factors
- 4.2. Drivers
 - 4.2.1. Rise in NASH-affected population
 - 4.2.2. Increasing prevalence of diabetes & obesity
 - 4.2.3. Driver
- 4.3. Restraints
 - 4.3.1. Insufficient diagnostic technologies for NASH
 - 4.3.2. Restraint
- 4.4. Opportunity
- 4.5. Impact analysis

5. INDUSTRY ANALYSIS

- 5.1. Porter's five forces analysis
- 5.2. Supply chain analysis
- 5.3. Pricing analysis
- 5.4. Regulatory analysis
- 5.5. Pipeline analysis

6. BY DRUG

- 6.1. Introduction
- 6.2. Market size analysis, and y-o-y growth analysis (%), By Drug segment
- 6.3. Market attractiveness index, By Drug segment
- 6.4. Vitamin E
 - 6.4.1. Introduction
 - 6.4.2. Market size analysis, y-o-y growth analysis (%)
- 6.5. Pioglitazone
- 6.6. Ocaliva
- 6.7. Elafibranor
- 6.8. Selonsertib & Cenicriviroc
- 6.9. Others

7. BY DISTRIBUTION CHANNELS

- 7.1. Introduction
- 7.2. Market size analysis, and y-o-y growth analysis (%), By Distribution Channels segment
- 7.3. Market attractiveness index, By Distribution Channels segment
- 7.4. Hospital pharmacy
 - 7.4.1. Introduction
 - 7.4.2. Market size analysis, and y-o-y growth analysis (%)
- 7.5. Retail pharmacy
- 7.6. Online providers

8. BY REGION

- 8.1. Introduction
- 8.2. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Region
- 8.3. Market Attractiveness Index, By Region
- 8.4. North America
 - 8.4.1. Introduction
 - 8.4.2. Key region-specific dynamics
 - 8.4.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Drug
 - 8.4.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Distribution Channels
 - 8.4.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Countries
 - 8.4.5.1. U.S.

8.4.5.2. Canada

8.4.5.3. Mexico

8.5. Europe

8.5.1. Introduction

8.5.2. Key Region-Specific Dynamics

8.5.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Drug

8.5.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Distribution Channels

8.5.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Countries

8.5.5.1. Germany

8.5.5.2. U.K.

8.5.5.3. France

8.5.5.4. Italy

8.5.5.5. Spain

8.5.5.6. Rest of Europe

8.6. South America

8.6.1. Introduction

8.6.2. Key Region-Specific Dynamics

8.6.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Drug

8.6.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Distribution Channels

8.6.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Countries

8.6.5.1. Brazil

8.6.5.2. Argentina

8.6.5.3. Rest of South America

8.7. Asia Pacific

8.7.1. Introduction

8.7.2. Key Region-Specific Dynamics

8.7.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Drug

8.7.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Distribution Channels

8.7.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Countries

8.7.5.1. China

8.7.5.2. India

8.7.5.3. Japan

8.7.5.4. Australia

8.7.5.5. Rest of Asia Pacific

8.8. The Middle East And Africa

8.8.1. Introduction

8.8.2. Key Region-Specific Dynamics

8.8.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Drug

8.8.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Distribution Channels

9. COMPETITIVE LANDSCAPE

- 9.1. Competitive scenario
- 9.2. Competitor strategy analysis
- 9.3. Comparative type portfolio analysis
- 9.4. Market positioning/share analysis
- 9.5. Mergers and acquisitions analysis

10. COMPANY PROFILES

- 10.1. Allergan plc.
 - 10.1.1. Company Overview
 - 10.1.2. Type Portfolio And Description
 - 10.1.3. Key Highlights
 - 10.1.4. Financial Overview
- 10.2. Pfizer Inc
- 10.3. Gilead Sciences, Inc.
- 10.4. Genfit SA
- 10.5. Novartis AG
- 10.6. Intercepts Pharmaceuticals
- 10.7. Cadila Healthcare Ltd
- 10.8. Novo Nordisk
- 10.9. Raptor Pharmaceutical Corp.
- 10.10. Galmed Pharmaceuticals Ltd.

11. PREMIUM INSIGHTS

12. DATAM INTELLIGENCE

- 12.1. Appendix
- 12.2. About us and services
- 12.3. Contact Us

I would like to order

Product name: Non-alcoholic Steatohepatitis Treatment Market 2026

Product link: <https://marketpublishers.com/r/N21D5997818CEN.html>

Price: US\$ 2,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/N21D5997818CEN.html>